Department of Clinical Pharmacy and Pharmacy Management, Nnamdi Azikiwe University, Awka, Nigeria.
Centre for Applied Health Economics, School of Medicine and Dentistry, Griffith University, Brisbane, Queensland, Australia.
BMC Health Serv Res. 2021 Jul 11;21(1):685. doi: 10.1186/s12913-021-06718-4.
In sub-Saharan Africa, there is increasing mortality and morbidity of adolescents due to poor linkage, retention in HIV care and adherence to antiretroviral therapy (ART). This is a result of limited adolescent-centred service delivery interventions. This cost-effectiveness and feasibility study were piggybacked on a cluster-randomized trial that assessed the impact of an adolescent-centred service delivery intervention. The service delivery intervention examined the impact of an incentive scheme consisting of conditional economic incentives and motivational interviewing on the health outcomes of adolescents living with HIV in Nigeria.
A cost-effectiveness analysis from the healthcare provider's perspective was performed to assess the cost per additional patient achieving undetected viral load through the proposed intervention. The cost-effectiveness of the incentive scheme over routine care was estimated using the incremental cost-effectiveness ratio (ICER), expressed as cost/patient who achieved an undetectable viral load. We performed a univariate sensitivity analysis to examine the effect of key parameters on the ICER. An in-depth interview was conducted on the healthcare personnel in the intervention arm to explore the feasibility of implementing the service delivery intervention in HIV treatment hospitals in Nigeria.
The ICER of the Incentive Scheme intervention compared to routine care was US$1419 per additional patient with undetectable viral load. Going by the cost-effectiveness threshold of US$1137 per quality-adjusted life-years suggested by Woods et al., 2016, the intervention was not cost-effective. The sensitivity test showed that the intervention will be cost-effective if the frequency of CD4 count and viral load tests are reduced from quarterly to triannually. Healthcare professionals reported that patients' acceptance of the intervention was very high.
The conditional economic incentives and motivational interviewing was not cost-effective, but can become cost-effective if the frequency of HIV quality of life indicator tests are performed 1-3 times per annum. Patients' acceptance of the intervention was very high. However, healthcare professionals believed that sustaining the intervention may be difficult unless factors such as government commitment and healthcare provider diligence are duly addressed.
This trial is registered in the WHO International Clinical Trials Registry through the WHO International Registry Network ( PACTR201806003040425 ).
在撒哈拉以南非洲地区,由于艾滋病毒护理的联系、保留和抗逆转录病毒治疗(ART)的依从性差,青少年的死亡率和发病率不断上升。这是由于青少年为中心的服务提供干预措施有限。这项成本效益和可行性研究是在一项评估以青少年为中心的服务提供干预措施对尼日利亚艾滋病毒感染者健康结果影响的集群随机试验的基础上进行的。
从医疗保健提供者的角度进行成本效益分析,以评估通过拟议干预措施使更多患者实现病毒载量不可检测的成本。使用增量成本效益比(ICER)估计激励方案相对于常规护理的成本效益,以每实现病毒载量不可检测的患者的成本表示。我们进行了单变量敏感性分析,以检查关键参数对 ICER 的影响。对干预组的医疗保健人员进行了深入访谈,以探讨在尼日利亚艾滋病毒治疗医院实施服务提供干预措施的可行性。
与常规护理相比,激励方案干预的 ICER 为每增加一名病毒载量不可检测的患者 1419 美元。根据 Woods 等人 2016 年提出的每增加一个质量调整生命年 1137 美元的成本效益阈值,该干预措施没有成本效益。敏感性测试表明,如果将 CD4 计数和病毒载量检测的频率从每季度降低到每三年一次,该干预措施将具有成本效益。医疗保健专业人员报告称,患者对该干预措施的接受度非常高。
有条件的经济激励和动机访谈并不具有成本效益,但如果每年进行 1-3 次艾滋病毒生活质量指标检测,该干预措施将具有成本效益。患者对该干预措施的接受度非常高。然而,医疗保健专业人员认为,除非适当解决政府承诺和医疗保健提供者勤奋等因素,否则维持该干预措施可能很困难。
该试验通过世界卫生组织国际临床试验注册平台在世界卫生组织国际注册网络(PACTR201806003040425)注册。